Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Cancer Letters|November 28, 2017
The future of mesenchymal stem cell-based therapeutic approaches for cancer - From cells to ghostsAndrea Mohr, Ralf ZwackaCell Biology International|January 2, 2007
In situ trapping of initiator caspases reveals intermediate surprisesAndrea Mohr, Ralf M ZwackaInvestigative Ophthalmology & Visual Science|July 27, 2007
Accommodative response in pre-presbyopes with visual impairment and its clinical implicationsSusan J Leat, Andrea MohrBMC Cancer|July 4, 2015
TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to killAndrea Mohr, Rui Yu, Ralf M ZwackaOncology Reports|April 11, 2009
The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cellsChirlei Büneker, Andrea Mohr, Ralf Michael ZwackaStem Cell Research|July 19, 2011
Both human and mouse mesenchymal stem cells promote breast cancer metastasisStella Maris Albarenque, Ralf Michael Zwacka, Andrea MohrMolecular and Cellular Biology|August 19, 2005
Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cellsLars Behrend, Andrea Mohr, Tatjana Dick, et al.Cancers|April 24, 2019
MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer CellsAndrea Mohr, Tianyuan Chu, Greg N Brooke, et al.Molecular Cancer Research : MCR|October 20, 2006
Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cellsSusanne J Braeuer, Chirlei Büneker, Andrea Mohr, et al.Cancer Letters|November 23, 2011
IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cellsChirlei Klein Büneker, Rui Yu, Laura Deedigan, et al.Pageof 3